$906 Million is the total value of Vivo Capital, LLC's 51 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 16.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRMY | Sell | Harmony Biosciences Holdings Inc | $150,598,000 | -24.6% | 3,400,261 | -16.9% | 16.63% | -17.1% |
| TIL | Instil Bio Inc | $60,436,000 | +4.8% | 12,486,787 | 0.0% | 6.67% | +15.2% | |
| Sell | Ventyx Biosciences Inc | $47,333,000 | +101.4% | 1,355,861 | -29.4% | 5.23% | +121.4% | |
| VRNA | Buy | Verona Pharma PLCads | $43,434,000 | +277.0% | 4,249,918 | +54.5% | 4.80% | +314.4% |
| ALXO | ALX Oncology Holdings Inc | $40,386,000 | +18.3% | 4,220,048 | 0.0% | 4.46% | +30.1% | |
| TARS | Sell | Tarsus Pharmaceuticals Inc | $38,729,000 | +14.7% | 2,262,200 | -2.2% | 4.28% | +26.1% |
| SVA | Sinovac Biotech Ltd. | $38,173,000 | 0.0% | 5,900,000 | 0.0% | 4.21% | +9.9% | |
| GERN | Geron Corp | $35,657,000 | +51.0% | 15,238,095 | 0.0% | 3.94% | +65.9% | |
| TERN | Buy | Terns Pharmaceuticals Inc | $34,747,000 | +423.8% | 5,899,372 | +120.5% | 3.84% | +476.0% |
| VRDN | Buy | Viridian Therapeutics Inc | $34,047,000 | +126.4% | 1,660,019 | +27.7% | 3.76% | +148.9% |
| COGT | Sell | Cogent Biosciences Inc | $28,108,000 | +62.2% | 1,883,941 | -1.9% | 3.10% | +78.3% |
| RLMD | Buy | Relmada Therapeutics Inc | $26,404,000 | +97.0% | 713,238 | +1.0% | 2.92% | +116.6% |
| ALLK | New | Allakos Inc | $25,215,000 | – | 4,120,134 | +100.0% | 2.78% | – |
| AMRS | Sell | Amyris, Inc | $22,632,000 | +5.1% | 7,750,828 | -33.4% | 2.50% | +15.5% |
| KALV | KalVista Pharmaceuticals Inc. | $22,252,000 | +47.5% | 1,533,559 | 0.0% | 2.46% | +62.2% | |
| KDNY | Chinook Therapeutics Inc | $17,146,000 | +12.4% | 872,151 | 0.0% | 1.89% | +23.6% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $15,079,000 | +11.1% | 146,025 | 0.0% | 1.66% | +22.2% | |
| AVDL | Avadel Pharmaceuticals PLCadr | $14,715,000 | +105.3% | 2,937,093 | 0.0% | 1.62% | +125.7% | |
| VERA | Vera Therapeutics Inc | $14,207,000 | +56.6% | 666,666 | 0.0% | 1.57% | +72.1% | |
| ACRS | Aclaris Therapeutics, Inc. | $14,144,000 | +12.7% | 898,631 | 0.0% | 1.56% | +23.9% | |
| IMPL | Impel NeuroPharma Inc | $14,049,000 | -47.7% | 2,884,789 | 0.0% | 1.55% | -42.6% | |
| New | Cincor Pharma Inc | $11,462,000 | – | 349,237 | +100.0% | 1.26% | – | |
| BLU | Bellus Health Inc | $10,741,000 | +14.3% | 1,017,152 | 0.0% | 1.19% | +25.6% | |
| LEGN | Legend Biotech Corp Sponsoredsponsored ads | $9,971,000 | -25.8% | 244,375 | 0.0% | 1.10% | -18.4% | |
| PCVX | New | Vaxcyte Inc | $9,708,000 | – | 404,508 | +100.0% | 1.07% | – |
| ZLAB | Zai Lab Ltd ADRadr | $9,286,000 | -1.4% | 271,528 | 0.0% | 1.02% | +8.4% | |
| New | Astria Therapeutics Inc | $9,040,000 | – | 1,000,000 | +100.0% | 1.00% | – | |
| MRUS | Merus NV | $8,853,000 | -11.5% | 442,000 | 0.0% | 0.98% | -2.8% | |
| ISEE | Sell | Iveric Bio Inc | $8,672,000 | -82.8% | 483,413 | -90.8% | 0.96% | -81.1% |
| IO Biotech Inc | $8,172,000 | -42.0% | 3,015,545 | 0.0% | 0.90% | -36.2% | ||
| STSA | Satsuma Pharmaceuticals Inc | $7,394,000 | +44.9% | 1,232,394 | 0.0% | 0.82% | +59.4% | |
| DYN | Dyne Therapeutics Inc | $7,336,000 | +84.9% | 577,642 | 0.0% | 0.81% | +103.5% | |
| Aadi Bioscience Inc | $7,200,000 | +14.7% | 509,572 | 0.0% | 0.80% | +26.2% | ||
| GTH | Genetron Holdings Ltdads | $6,351,000 | -54.0% | 8,124,174 | 0.0% | 0.70% | -49.5% | |
| IOVA | Iovance Biotherapeutics Inc | $6,275,000 | -13.2% | 655,057 | 0.0% | 0.69% | -4.5% | |
| BOLT | Bolt Therapeutics Inc | $5,730,000 | -27.4% | 3,871,291 | 0.0% | 0.63% | -20.2% | |
| CLDX | Sell | Celldex Therapeutics Inc | $5,593,000 | -62.9% | 198,983 | -64.4% | 0.62% | -59.2% |
| DBVT | New | DBV Technologies SAsponsored adr | $4,795,000 | – | 2,708,875 | +100.0% | 0.53% | – |
| OLMA | Olema Pharmaceuticals Inc | $4,663,000 | -32.2% | 1,689,515 | 0.0% | 0.52% | -25.4% | |
| CMPX | Compass Therapeutics Inc | $4,560,000 | -14.0% | 2,000,000 | 0.0% | 0.50% | -5.5% | |
| ARWR | Arrowhead Pharmaceuticals Inc | $4,541,000 | -6.1% | 137,411 | 0.0% | 0.50% | +3.1% | |
| ALGS | Aligos Therapeutics Inc | $3,902,000 | -9.1% | 3,547,030 | 0.0% | 0.43% | 0.0% | |
| GRCL | Gracell Biotechnologies Incsponsored ads | $3,096,000 | -41.4% | 961,359 | 0.0% | 0.34% | -35.6% | |
| Sera Prognostics Inc | $2,970,000 | -2.4% | 1,856,011 | 0.0% | 0.33% | +7.2% | ||
| CDXS | Codexis, Inc | $2,352,000 | -42.1% | 388,144 | 0.0% | 0.26% | -36.3% | |
| Minerva Surgical Inc | $1,762,000 | -66.2% | 2,215,667 | 0.0% | 0.20% | -62.7% | ||
| ASLN | Aslan Pharmaceuticals Ltdads | $1,701,000 | +21.0% | 2,840,909 | 0.0% | 0.19% | +33.3% | |
| RZLT | Rezolute Inc | $1,341,000 | -15.2% | 489,473 | 0.0% | 0.15% | -6.9% | |
| FIXX | Homology Medicines, Inc. | $596,000 | -18.2% | 370,068 | 0.0% | 0.07% | -9.6% | |
| DTIL | Precision Biosciences Inc | $182,000 | -18.8% | 140,255 | 0.0% | 0.02% | -9.1% | |
| MTCR | Metacrine Inc | $71,000 | -2.7% | 146,426 | 0.0% | 0.01% | +14.3% | |
| ZYME | Exit | Zymeworks Inc | $0 | – | -286,064 | -100.0% | -0.15% | – |
| DSGN | Exit | Design Therapeutics | $0 | – | -476,589 | -100.0% | -0.67% | – |
| SRRA | Exit | Sierra Oncology, Inc | $0 | – | -3,329,509 | -100.0% | -18.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.